Lexicon Pharmaceuticals (LXRX) Accounts Payables (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Accounts Payables data on file, last reported at $3.0 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.0 million, down 71.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 million (down 71.97% YoY), and the FY2025 annual result was $3.1 million, down 79.17% from the prior year.
• Accounts Payables fell to $3.0 million in Q1 2026 per LXRX's latest filing, from $3.1 million in the prior quarter.
• Over five years, Accounts Payables peaked at $14.8 million in Q4 2024 and troughed at $3.0 million in Q1 2026.
• A 5-year average of $9.4 million and a median of $10.3 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 89.22% in 2022, then plunged 79.17% in 2025.
• A 5-year view of Accounts Payables shows it stood at $10.4 million in 2022, then soared by 38.42% to $14.4 million in 2023, then increased by 2.86% to $14.8 million in 2024, then sank by 79.17% to $3.1 million in 2025, then retreated by 2.82% to $3.0 million in 2026.
• Business Quant data shows LXRX's Accounts Payables at $3.0 million in Q1 2026, $3.1 million in Q4 2025, and $3.8 million in Q3 2025.